Prescription omega-3 fatty acid products: considerations for patients with diabetes mellitus

Nadeem Tajuddin,1 Ali Shaikh,2 Amir Hassan2 1Department of Internal Medicine, Baylor College of Medicine, Houston, TX, USA; 2Clinic of Endocrinology, Houston, TX, USA Abstract: Type 2 diabetes mellitus (T2DM) and metabolic syndrome contribute to hypertriglyceridemia, which may increase residual ris...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Tajuddin N, Shaikh A, Hassan A
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2016
Materias:	Docosahexaenoic acid Eicosapentaenoic acid Hypertriglyceridemia Icosapent ethyl Omega-3 fatty acids Triglycerides Type 2 diabetes mellitus Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/2d46fa35d9644000b2b9f5fac825805f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2d46fa35d9644000b2b9f5fac825805f
record_format	dspace
spelling	oai:doaj.org-article:2d46fa35d9644000b2b9f5fac825805f2021-12-02T02:52:36ZPrescription omega-3 fatty acid products: considerations for patients with diabetes mellitus1178-7007https://doaj.org/article/2d46fa35d9644000b2b9f5fac825805f2016-04-01T00:00:00Zhttps://www.dovepress.com/prescription-omega-3-fatty-acid-products-considerations-for-patients-w-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Nadeem Tajuddin,1 Ali Shaikh,2 Amir Hassan2 1Department of Internal Medicine, Baylor College of Medicine, Houston, TX, USA; 2Clinic of Endocrinology, Houston, TX, USA Abstract: Type 2 diabetes mellitus (T2DM) and metabolic syndrome contribute to hypertriglyceridemia, which may increase residual risk of cardiovascular disease in patients with elevated triglyceride (TG) levels despite optimal low-density lipoprotein cholesterol (LDL-C) levels with statin therapy. Prescription products containing the long-chain omega-3 fatty acids (OM3FAs) eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are an effective strategy for reducing TG levels. This article provides an overview of prescription OM3FAs, including relevant clinical data in patients with T2DM and/or metabolic syndrome. Prescription OM3FAs contain either combinations of DHA and EPA (omega-3-acid ethyl esters, omega-3-carboxylic acids, omega-3-acid ethyl esters A) or EPA alone (icosapent ethyl). These products are well tolerated and can be used safely with statins. Randomized controlled trials have demonstrated that all prescription OM3FAs produce statistically significant reductions in TG levels compared with placebo; however, differential effects on LDL-C levels have been reported. Products containing DHA may increase LDL-C levels, whereas the EPA-only product did not increase LDL-C levels compared with placebo. Because increases in LDL-C levels may be unwanted in patients with T2DM and/or dyslipidemia, the EPA-only product should not be replaced with products containing DHA. Available data on the effects of OM3FAs in patients with diabetes and/or metabolic syndrome support that these products can be used safely in patients with T2DM and have beneficial effects on atherogenic parameters; in particular, the EPA-only prescription product significantly reduced TG, non-high-density lipoprotein cholesterol, Apo B, remnant lipoprotein cholesterol, and high-sensitivity CRP levels without increasing LDL-C levels compared with placebo. Ongoing studies of the effects of prescription OM3FAs on cardiovascular outcomes will help determine whether these products will emerge as effective add-on options to statin therapy for reduction of residual cardiovascular disease risk. Keywords: docosahexaenoic acid, dyslipidemia, eicosapentaenoic acid, hypertriglyceridemia, icosapent ethyl, omega-3 fatty acids, triglyceridesTajuddin NShaikh AHassan ADove Medical PressarticleDocosahexaenoic acidEicosapentaenoic acidHypertriglyceridemiaIcosapent ethylOmega-3 fatty acidsTriglyceridesType 2 diabetes mellitusSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol 2016, Iss Issue 1, Pp 109-118 (2016)
institution	DOAJ
collection	DOAJ
language	EN
topic	Docosahexaenoic acid Eicosapentaenoic acid Hypertriglyceridemia Icosapent ethyl Omega-3 fatty acids Triglycerides Type 2 diabetes mellitus Specialties of internal medicine RC581-951
spellingShingle	Docosahexaenoic acid Eicosapentaenoic acid Hypertriglyceridemia Icosapent ethyl Omega-3 fatty acids Triglycerides Type 2 diabetes mellitus Specialties of internal medicine RC581-951 Tajuddin N Shaikh A Hassan A Prescription omega-3 fatty acid products: considerations for patients with diabetes mellitus
description	Nadeem Tajuddin,1 Ali Shaikh,2 Amir Hassan2 1Department of Internal Medicine, Baylor College of Medicine, Houston, TX, USA; 2Clinic of Endocrinology, Houston, TX, USA Abstract: Type 2 diabetes mellitus (T2DM) and metabolic syndrome contribute to hypertriglyceridemia, which may increase residual risk of cardiovascular disease in patients with elevated triglyceride (TG) levels despite optimal low-density lipoprotein cholesterol (LDL-C) levels with statin therapy. Prescription products containing the long-chain omega-3 fatty acids (OM3FAs) eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are an effective strategy for reducing TG levels. This article provides an overview of prescription OM3FAs, including relevant clinical data in patients with T2DM and/or metabolic syndrome. Prescription OM3FAs contain either combinations of DHA and EPA (omega-3-acid ethyl esters, omega-3-carboxylic acids, omega-3-acid ethyl esters A) or EPA alone (icosapent ethyl). These products are well tolerated and can be used safely with statins. Randomized controlled trials have demonstrated that all prescription OM3FAs produce statistically significant reductions in TG levels compared with placebo; however, differential effects on LDL-C levels have been reported. Products containing DHA may increase LDL-C levels, whereas the EPA-only product did not increase LDL-C levels compared with placebo. Because increases in LDL-C levels may be unwanted in patients with T2DM and/or dyslipidemia, the EPA-only product should not be replaced with products containing DHA. Available data on the effects of OM3FAs in patients with diabetes and/or metabolic syndrome support that these products can be used safely in patients with T2DM and have beneficial effects on atherogenic parameters; in particular, the EPA-only prescription product significantly reduced TG, non-high-density lipoprotein cholesterol, Apo B, remnant lipoprotein cholesterol, and high-sensitivity CRP levels without increasing LDL-C levels compared with placebo. Ongoing studies of the effects of prescription OM3FAs on cardiovascular outcomes will help determine whether these products will emerge as effective add-on options to statin therapy for reduction of residual cardiovascular disease risk. Keywords: docosahexaenoic acid, dyslipidemia, eicosapentaenoic acid, hypertriglyceridemia, icosapent ethyl, omega-3 fatty acids, triglycerides
format	article
author	Tajuddin N Shaikh A Hassan A
author_facet	Tajuddin N Shaikh A Hassan A
author_sort	Tajuddin N
title	Prescription omega-3 fatty acid products: considerations for patients with diabetes mellitus
title_short	Prescription omega-3 fatty acid products: considerations for patients with diabetes mellitus
title_full	Prescription omega-3 fatty acid products: considerations for patients with diabetes mellitus
title_fullStr	Prescription omega-3 fatty acid products: considerations for patients with diabetes mellitus
title_full_unstemmed	Prescription omega-3 fatty acid products: considerations for patients with diabetes mellitus
title_sort	prescription omega-3 fatty acid products: considerations for patients with diabetes mellitus
publisher	Dove Medical Press
publishDate	2016
url	https://doaj.org/article/2d46fa35d9644000b2b9f5fac825805f
work_keys_str_mv	AT tajuddinn prescriptionomega3fattyacidproductsconsiderationsforpatientswithdiabetesmellitus AT shaikha prescriptionomega3fattyacidproductsconsiderationsforpatientswithdiabetesmellitus AT hassana prescriptionomega3fattyacidproductsconsiderationsforpatientswithdiabetesmellitus
_version_	1718402092724387840

Prescription omega-3 fatty acid products: considerations for patients with diabetes mellitus

Ejemplares similares